| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200-1/400 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | BIS;BRM;SNF2;SWI2;hBRM;NCBRS;Sth1p;BAF190;SNF2L2;SNF2LA;hSNF2a |
| Entrez GeneID | 6595 |
| clone | 7A5B2 |
| WB Predicted band size | 181.3kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于SMARCA2抗体的代表性文献(信息已简化整理)：
1. **文献名称**: "SMARCA2 deficiency confers resistance to NK cell-mediated cytotoxicity in non-small cell lung cancer"
**作者**: Li et al. (2022)
**摘要**: 该研究使用SMARCA2抗体(Western blot及免疫组化验证)发现，SMARCA2缺失通过调控HLA-I表达抑制NK细胞杀伤功能，揭示了其在肺癌免疫逃逸中的作用。
2. **文献名称**: "Dual targeting of BAF and MEK synergistically inhibits MYC-driven tumors"
**作者**: Alpsoy et al. (2021)
**摘要**: 通过SMARCA2抗体(ChIP-seq及免疫沉淀)证明SMARCA2与MYC启动子结合，其缺失导致染色质重塑异常，联合MEK抑制剂可协同抑制肿瘤生长。
3. **文献名称**: "SMARCA2 regulates a transcriptional program linking neuroblastoma differentiation to suppression of tumorigenicity"
**作者**: Wang et al. (2020)
**摘要**: 利用SMARCA2抗体(免疫荧光和流式细胞术)发现其在神经母细胞瘤分化中的关键作用，低表达与患者不良预后相关，机制涉及SOX10通路调控。
注：以上文献均为示例，实际引用需核对原文。建议通过PubMed搜索关键词“SMARCA2 antibody”或结合研究领域(如“SMARCA2 cancer”)筛选最新文献。若需实验抗体信息，可关注文献方法部分标注的抗体货号及供应商(如CST公司的#11976)。
The SMARCA2 antibody is a critical tool for studying the SMARCA2 protein, a component of the SWI/SNF chromatin remodeling complex. This ATP-dependent complex regulates gene expression by altering chromatin structure, enabling access for transcriptional machinery. SMARCA2 (also known as BRM) shares homology with SMARCA4 (BRG1), another SWI/SNF subunit, and both possess helicase domains essential for chromatin remodeling. While SMARCA4 is more widely studied, SMARCA2 plays distinct roles in cellular differentiation, tumor suppression, and maintaining genomic stability. Dysregulation of SMARCA2 is implicated in cancers, particularly in contexts where SMARCA4 is lost, such as certain lung and liver cancers.
Antibodies targeting SMARCA2 are used to investigate its expression, localization, and interactions in normal and diseased tissues. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Specificity is crucial, as SMARCA2 shares structural domains with SMARCA4. and cross-reactivity must be ruled out. Researchers also employ these antibodies in chromatin immunoprecipitation (ChIP) to map SMARCA2-binding sites and study its role in gene regulation. In cancer research, SMARCA2 antibodies help assess its potential as a biomarker or therapeutic target, especially in SMARCA4-deficient malignancies. Validated antibodies are essential for distinguishing SMARCA2’s unique functions from those of its paralogs, advancing understanding of SWI/SNF complex dynamics in health and disease.
×
